Pierre Fabre Laboratories Selects Dassault Systèmes’ Version 6 Platform to Deploy
2011/11/22Leading Pharmaceutical and Dermo-cosmetics Group Replaces Most of its Existing Product Development Applications
with Single PLM Platform;
Develop more cross-cutting activities, improve time to market and improve product traceability
PARIS (European Customer Forum), November 22, 2011 — Dassault Systèmes (Euronext Paris: #13065, DSY.PA), a world leader in 3D and Product Lifecycle Management (PLM) solutions, today announced that Pierre Fabre Laboratories has selected its ENOVIA Version 6 solution as its PLM platform. Delivering an up-to-the-minute, enterprise-wide vision of raw material and substance flows, as well as all associated regulatory documents and data, Dassault Systèmes’ Version 6 platform will support the international expansion of Pierre Fabre Médicament (pharmaceuticals), Pierre Fabre Santé (family health) and Pierre Fabre Dermo-cosmétique (dermo-cosmetics).
Deployment will be phased in over the next four years. ENOVIA has already been successfully implemented to manage Pierre Fabre Laboratories' global dermo-cosmetics product portfolio, including formulas, raw materials, substances and country-specific products. As the backbone of this transformation, ENOVIA provides the enterprise-wide repository for full lifecycle product-related information, facilitating real-time collaboration and decision-making among all departments – from purchasing and development to regulatory affairs, quality assurance, affiliates and partners.
"Developing and marketing drugs, family health and dermo-cosmetic products involves complex processes, which are subject to compliance with strict patient and consumer safety regulations. Traceability is the watchword in all processes and decision-making," said Sylvie Touya, head of Strategic Programs, Pierre Fabre Laboratories. “Configured to the requirements of each phase involved in these three core businesses, PLM will enable us to achieve maximum traceability. As well as optimizing processes, PLM will help us achieve our goals of accelerating time to market, improving compliance, expanding internationally and driving innovation.”
"The partnership between our two companies illustrates Dassault Systèmes’ strong commitment to the life sciences industry," said Jean Colombel, vice president, Life Sciences industry, Dassault Systèmes. "As a centralized collaborative repository, ENOVIA Version 6 provides the common platform that companies need to ease collaboration across their organization and achieve their strategic innovation, compliance management and IP capitalization objectives."
###
Pierre Fabre Laboratories
Pierre Fabre Laboratories, the second largest independent pharmaceutical laboratory in France, posted revenue of €1.86 billion in 2010, with international sales accounting for more than 50%. The company employs around 10,000 people, including 1,300 in R&D. Business spans pharmaceutical drugs, OTC family health and dermo-cosmetics (including brands like Avène, A-Derma, Ducray, Elancyl, Galénic, Glytone, Klorane and René Furterer). In 2010, Pierre Fabre Laboratories invested 22% of annual revenue from its pharmaceutical drug business in R&D, focusing on three main areas: oncology, central nervous system and dermatology.
ダッソー・システムズについて
ダッソー・システムズは、3DとPLMソリューションにおけるワールド・リーダーとして、80カ国以上、130,000以上のお客様にそのバリューを提供しています。1981年から3Dソフトウエア市場におけるパイオニアであるダッソー・システムズは、業界プロセスを支援するPLMアプリケーション・ソフトウエアおよびサービスを開発・販売し、コンセプト設計からメンテナンス、リサイクルに至る全製品ライフサイクルにおける3Dビジョンを提供します。提供内容は、バーチャル製品設計のためのCATIA、バーチャル・プロダクションのためのDELMIA、バーチャル･テスティングのためのSIMULIA、グローバルなコラボレーティブ・ライフサイクル・マネジメントのENOVIA、検索アプリケーションのEXALEAD、3Dメカニカル設計のためのSolidWorks、オンライン3Dライフライク・エクスペリエンスの3DVIAが含まれます。その他詳細については次のサイトをご覧ください。URL: http://www.3ds.com （英語）、 http://www.3ds.com/jp (日本語)
CATIA、DELMIA、ENOVIA、EXALEAD、SIMULIA、SolidWorks、および3DVIAは、ダッソー・システムズ（Dassault Systèmes）もしくはダッソー・システムズの子会社の米国およびその他の国における登録商標です。